WuXi Biologics (Cayman) (HKSE:02269) Other Current Payables : HK$2,091 Mil (As of Dec. 2024)

View and export this data going back to 2017. Start your Free Trial

What is WuXi Biologics (Cayman) Other Current Payables?

WuXi Biologics (Cayman)'s Other Current Payables for the quarter that ended in Dec. 2024 was HK$2,091 Mil.

WuXi Biologics (Cayman)'s quarterly Other Current Payables declined from Dec. 2023 (HK$2,008 Mil) to Jun. 2024 (HK$869 Mil) but then increased from Jun. 2024 (HK$869 Mil) to Dec. 2024 (HK$2,091 Mil).

WuXi Biologics (Cayman)'s annual Other Current Payables declined from Dec. 2022 (HK$2,699 Mil) to Dec. 2023 (HK$2,008 Mil) but then increased from Dec. 2023 (HK$2,008 Mil) to Dec. 2024 (HK$2,091 Mil).

WuXi Biologics (Cayman) Other Current Payables Historical Data

The historical data trend for WuXi Biologics (Cayman)'s Other Current Payables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

WuXi Biologics (Cayman) Other Current Payables Chart

WuXi Biologics (Cayman) Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Other Current Payables

Get a 7-Day Free Trial

2,431.78

3,711.36

2,699.42

2,008.48

2,090.89

WuXi Biologics (Cayman) Semi-Annual Data
	Dec14	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24	Dec24
Other Current Payables	Get a 7-Day Free Trial															2,699.42	1,043.87	2,008.48	868.62	2,090.89

WuXi Biologics (Cayman) Other Current Payables Calculation

Other Current Payables is the payables owed and expected to be paid within one year or one operating cycle that not otherwise classified. It includes dividends payable and all other current payables.

WuXi Biologics (Cayman) Other Current Payables Related Terms

Thank you for viewing the detailed overview of WuXi Biologics (Cayman)'s Other Current Payables provided by GuruFocus.com. Please click on the following links to see related term pages.

WuXi Biologics (Cayman) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » WuXi Biologics (Cayman) Inc (HKSE:02269) » Definitions » Other Current Payables

Comparable Companies

Traded in Other Exchanges

WXIBF:USA WXXWY:USA 1FW2:Germany

Address

No. 108, Meiliang Road, Mashan Binhu District, Wuxi, CHN, 214092

Website

https://www.wuxibiologics.com

WuXi Biologics is one of the largest global biologic global contract development and manufacturing organizations. WuXi Biologics, incorporated in 2014 following the reorganization of WuXi PharmaTech, later known as WuXi AppTec, now has global revenue of CNY 18.7 billion. North America represented 57.3% of total revenue in 2024. The firm has a "follow and win the molecule" strategy by providing end-to-end services, from drug discovery to commercial manufacturing. It also adopts a global dual sourcing strategy by providing drug products and drug substance manufacturing.

Executives

Li Ge	2201 Interest of corporation controlled by you
Liu Xiaozhong	2401 A concert party to an agreement to buy shares
New Wuxi Life Science Holdings Limited	2201 Interest of corporation controlled by you
New Wuxi Life Science Limited	2201 Interest of corporation controlled by you
Wuxi Biologics Holdings Limited	2101 Beneficial owner
Wuxi Pharmatech (cayman) Inc.	2201 Interest of corporation controlled by you
Zhang Zhaohui	2401 A concert party to an agreement to buy shares
Blackrock, Inc.	2201 Interest of corporation controlled by you
Jpmorgan Chase & Co.	2201 Interest of corporation controlled by you
Citigroup Inc.	2502 Approved lending agent
Brown Brothers Harriman & Co.	2502 Approved lending agent
Zhao Ning	2202 Interest of your spouse
The Capital Group Companies, Inc.	2201 Interest of corporation controlled by you

WuXi Biologics (Cayman) Headlines

No Headlines